6794 — Unicocell Biomed Co Income Statement
0.000.00%
Last trade - 00:00
- TWD4.53bn
- TWD4.15bn
- TWD24.59m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 15.7 | 3.98 | 8.18 | 14.4 | 24.6 |
Cost of Revenue | |||||
Gross Profit | 12.5 | 2.34 | 5.83 | 8.2 | 17.9 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Total Operating Expenses | 117 | 115 | 95.5 | 107 | 121 |
Operating Profit | -101 | -111 | -87.3 | -92.1 | -96.3 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -101 | -109 | -86.4 | -91.2 | -84.1 |
Provision for Income Taxes | |||||
Net Income After Taxes | -101 | -109 | -86.4 | -91.2 | -84.1 |
Net Income Before Extraordinary Items | |||||
Net Income | -101 | -109 | -86.4 | -91.2 | -84.1 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -101 | -109 | -86.4 | -91.2 | -84.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -3.3 | -3.05 | -2.27 | -2.2 | -1.65 |
Dividends per Share |